Chung-Chieh Wang

Dr. Chung-Chieh Wang

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CWChung-Chieh Wang
Chung-Chieh Wang
YTYu-Chieh Tsai
Yu-Chieh Tsai
YJYung-Ming Jeng
Yung-Ming Jeng
Genetic profiling studies on muscle-invasive bladder cancers (MIBCs) have discovered molecular subtypes with different biological characteristics. Immunohistochemical (IHC) markers such as GATA3, cytokeratin (CK) 20, CK5/6, and p53 are associated with these subtypes. In this study, we investigated the biological and prognostic significance of these IHC markers in MIBCs from 91 patients who underwent radical cystectomy. High Ki-67 indices were associated with negative CK20 (p = 0.002) and diffuse CK5/6 (p = 0.001) staining. By contrast, tumors with diffuse GATA3 expression had low Ki-67 index (p = 0.006). Regarding p53, three staining patterns were associated with a high Ki-67 index: (1) complete absence, (2) diffusely strong nuclear reactivity, and (3) diffusely strong cytoplasmic staining (p < 0.001 compared with other patterns). CK5/6 and CK20 expression was typically present in a reciprocal fashion; however, diffuse GATA3 and CK5/6 coexpression was observed in 13 (14.29%) cases. Among 78 chemotherapy-naïve patients, low GATA3 staining was associated with worse recurrence-free survival in both univariate (p = 0.008) and multivariate analyses (p = 0.002). CK20, CK5/6, or p53 expression was not associated with clinical outcome. Based on our results, IHC staining for GATA3 may help risk stratification in patients with MIBC receiving radical cystectomy. In addition, the differences in Ki-67 indices suggested that aberrant p53 expression was better defined by the three aforementioned patterns, rather than percentage of nuclear staining alone.

28 November 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
CWChung-Chieh Wang
Chung-Chieh Wang
CHChao-Yuan Huang
Chao-Yuan Huang
YJYu‐Lin Jhuang
Yu‐Lin Jhuang
CCChih‐Chi Chen
Chih‐Chi Chen
YJYung-Ming Jeng
Yung-Ming Jeng

1 May 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
JHJian-Hua Hong
Jian-Hua Hong
PLPriscilla Ann Hweek Lee
Priscilla Ann Hweek Lee
YLYu-Chuan Lu
Yu-Chuan Lu
CHCheng-Yu Huang
Cheng-Yu Huang
CCChung-Hsin Chen
Chung-Hsin Chen
HWHsiang-Tsui Wang
Hsiang-Tsui Wang

13 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YCYun Chiang
Yun Chiang
CWChung-Chieh Wang
Chung-Chieh Wang
YTYu-Chieh Tsai
Yu-Chieh Tsai
CHChao-Yuan Huang
Chao-Yuan Huang
YPYeong-Shiau Pu
Yeong-Shiau Pu
CLChia-Chi Lin
Chia-Chi Lin
The aim of this study was to investigate prognostic molecular targets for selecting patients with muscle-invasive bladder cancer undergoing bladder-preserving therapy. Pretreatment biopsy samples from patients with muscle-invasive bladder cancer receiving trimodality bladder-preserving therapy were analyzed for expression levels of p53, p16, human epidermal growth factor receptor-2 (Her-2), epidermal growth factor receptor (EGFR), nuclear factor-kappa B (NFκB; p65), E-cadherin, matrix metalloproteinase-9 (MMP9), meiotic recombination 11 homolog (MRE11), programmed death-1 ligand (PD-L1), and mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6) by immunohistochemical (IHC) staining. The correlations between these molecular markers with local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and overall survival (OS) were explored. Biopsy samples from 41 out of 60 patients were evaluated using IHC. Univariate analysis revealed that the high expression of NFκB is associated with significantly worse LPFS, DMFS, and OS, and low expression of p16 is associated with significantly lower LPFS. Upon further multivariate analysis including sex, age, stage, and selected unfavorable factors in the model, NFκB and p16 independently remained significant. The investigational in vitro study demonstrated that irradiation induces up-regulation of NFκB signaling. Irradiated bladder cancer cells showed increased invasion capability and clonogenic survival; inhibition of NFκB signaling by an NFκB inhibitor, SC75741, or RNA interference reversed the observed increases. NFκB expression (p65) is associated with prognostic significance for both LPFS and DMFS in patients treated with bladder-preserving therapy, with consistent impact on cell viability of bladder cancer cells. NFκB may be a putative molecular target to help with outcome stratification.

27 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FHFU-JEN HSUEH
FU-JEN HSUEH
CWChung-Chieh Wang
Chung-Chieh Wang
JGJhe-Cyuan Guo
Jhe-Cyuan Guo
SCShih-Chieh Chueh
Shih-Chieh Chueh
YTYu-Chieh Tsai
Yu-Chieh Tsai
Metastatic urothelial carcinoma (mUC) is a highly aggressive malignancy

7 July 2026 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
FHFU-JEN HSUEH
FU-JEN HSUEH
CWChung-Chieh Wang
Chung-Chieh Wang
CHChia-Lang Hsu
Chia-Lang Hsu
SWShu-Cheng Wu
Shu-Cheng Wu
JGJhe-Cyuan Guo
Jhe-Cyuan Guo
YTYu-Chieh Tsai
Yu-Chieh Tsai
Background: Nectin-4 is a key therapeutic target of antibody–drug conjugates (ADCs) in advanced urothelial carcinoma (UC), but its expression patterns and underlying biology across anatomical sites remain poorly understood. Objectives: This study aimed to elucidate Nectin-4-related features in bladder (urinary bladder carcinoma, UBC) and upper urinary tract (upper tract urothelial carcinoma, UTUC) through a multi-layered approach, including primary tumor characterization, paired primary–metastatic analyses, and immune transcriptomic profiling. Design: A retrospective cohort study. Methods: We retrospectively analyzed primary tumors from 139 patients with advanced UC, including 56 with paired metastatic specimens and 75 with sufficient primary tumor tissue for immune profiling. Membranous Nectin-4 expression was assessed by immunohistochemistry and categorized as Nectin-4 High (H-score 100–300) or Nectin-4 Low (0–99). Immune profiling was performed using the nCounter ® PanCancer Immune Profiling Panel (NanoString Technologies). External transcriptomic datasets (UBC: TCGA-BLCA; UTUC: GSE244957) were used to assess the consistency of immune profiling results. Results: Primary UBC tumors exhibited significantly higher Nectin-4 expression than UTUC tumors (median H-score 150.0 vs 95.0, p = 0.005; Nectin-4 High 70.6% vs 50.0%, p = 0.018). Among paired specimens, 33.9% (19/56) showed primary–metastatic changes in Nectin-4 status, which occurred more frequently in UBC than in UTUC (52.2% vs 21.2%, p = 0.017). Immune profiling revealed a relatively immune-depleted pattern in Nectin-4 High versus Nectin-4 Low tumors in UBC, whereas this pattern was less evident in UTUC. These findings were consistent with those from external transcriptomic datasets. Conclusion: UBC and UTUC demonstrate distinct Nectin-4 expression patterns and associated immune contexture, highlighting the biological heterogeneity of Nectin-4 in advanced UC. Further prospective studies are warranted to validate these findings and clarify their clinical implications.